Literature DB >> 21390187

Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice.

Yifat Edrei1, Eitan Gross, Nathalie Corchia, Galia Tsarfaty, Eithan Galun, Orit Pappo, Rinat Abramovitch.   

Abstract

Recently, we have demonstrated the feasibility of using hemodynamic response imaging (HRI), a functional magnetic resonance imaging (MRI) method combined with hypercapnia and hyperoxia, for monitoring vascular changes during liver pathologies without the need of contrast material. In this study, we evaluated HRI ability to assess changes in liver tumor vasculature during tumor establishment, progression, and antiangiogenic therapy. Colorectal adenocarcinoma cells were injected intrasplenically to model colorectal liver metastasis (CRLM) and the Mdr2 knockout mice were used to model primary hepatic tumors. Hepatic perfusion parameters were evaluated using the HRI protocol and were compared with contrast-enhanced (CE) MRI. The hypovascularity and the increased arterial blood supply in well-defined CRLM were demonstrated by HRI. In CRLM-bearing mice, the entire liver perfusion was attenuated as the HRI maps were significantly reduced by 35%. This study demonstrates that the HRI method showed enhanced sensitivity for small CRLM (1-2 mm) detection compared with CE-MRI (82% versus 38%, respectively). In addition, HRI could demonstrate the vasculature alteration during CRLM progression (arborized vessels), which was further confirmed by histology. Moreover, HRI revealed the vascular changes induced by rapamycin treatment. Finally, HRI facilitates primary hepatic tumor characterization with good correlation to the pathologic differentiation. The HRI method is highly sensitive to subtle hemodynamic changes induced by CRLM and, hence, can function as an imaging tool for understanding the hemodynamic changes occurring during CRLM establishment, progression, and antiangiogenic treatment. In addition, this method facilitated the differentiation between different types of hepatic lesions based on their vascular profile noninvasively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21390187      PMCID: PMC3050867          DOI: 10.1593/neo.101354

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  48 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Effect of occult hepatic metastases on survival after curative resection for colorectal carcinoma.

Authors:  I G Finlay; C S McArdle
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

Review 3.  Imaging liver metastases: current limitations and future prospects.

Authors:  P J Robinson
Journal:  Br J Radiol       Date:  2000-03       Impact factor: 3.039

4.  Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.

Authors:  Fu L Luan; Minoru Hojo; Mary Maluccio; Kouzaburo Yamaji; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2002-05-27       Impact factor: 4.939

Review 5.  Treatment of liver metastases, an update on the possibilities and results.

Authors:  T Ruers; R P Bleichrodt
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

6.  PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

Authors:  Joachim Drevs; Ralph Müller-Driver; Christine Wittig; Stefan Fuxius; Norbert Esser; Harald Hugenschmidt; Moritz A Konerding; Peter R Allegrini; Jeanette Wood; Jürgen Hennig; Clemens Unger; Dieter Marmé
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Deranged liver blood flow patterns in the detection of liver metastases.

Authors:  S H Leveson; P A Wiggins; G R Giles; A Parkin; P J Robinson
Journal:  Br J Surg       Date:  1985-02       Impact factor: 6.939

8.  Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

Authors:  Jeffrey L Evelhoch; Patricia M LoRusso; Zhanquan He; Zachary DelProposto; Lisa Polin; Thomas H Corbett; Peter Langmuir; Catherine Wheeler; Andrew Stone; Joanna Leadbetter; Anderson J Ryan; David C Blakey; John C Waterton
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Rapamycin is an effective inhibitor of human renal cancer metastasis.

Authors:  Fu L Luan; Ruchuang Ding; Vijay K Sharma; W James Chon; Milagros Lagman; Manikkam Suthanthiran
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

10.  Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.

Authors:  D Checkley; J J Tessier; J Kendrew; J C Waterton; S R Wedge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more
  11 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Photothermal cancer therapy by gold-ferrite nanocomposite and near-infrared laser in animal model.

Authors:  M Heidari; N Sattarahmady; N Azarpira; H Heli; A R Mehdizadeh; T Zare
Journal:  Lasers Med Sci       Date:  2015-12-22       Impact factor: 3.161

Review 4.  Non-invasive diagnostic imaging of colorectal liver metastases.

Authors:  Pier Paolo Mainenti; Federica Romano; Laura Pizzuti; Sabrina Segreto; Giovanni Storto; Lorenzo Mannelli; Massimo Imbriaco; Luigi Camera; Simone Maurea
Journal:  World J Radiol       Date:  2015-07-28

5.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

6.  Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.

Authors:  Y Edrei; E Gross; N Corchia; R Abramovitch
Journal:  Br J Cancer       Date:  2012-07-17       Impact factor: 7.640

7.  Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Authors:  Paul R Territo; Mary Maluccio; Amanda A Riley; Brian P McCarthy; James Fletcher; Mark Tann; Romil Saxena; Nicholas J Skill
Journal:  BMC Med Imaging       Date:  2015-05-16       Impact factor: 1.930

8.  TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.

Authors:  Chani Komar-Stossel; Eitan Gross; Elia Dery; Nathalie Corchia; Karen Meir; Iris Fried; Rinat Abramovitch
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

9.  Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles.

Authors:  Yang Guo; Zhuoli Zhang; Dong-Hyun Kim; Weiguo Li; Jodi Nicolai; Daniel Procissi; Yi Huan; Guohong Han; Reed A Omary; Andrew C Larson
Journal:  Int J Nanomedicine       Date:  2013-09-06

10.  Effect of hyperoxia and hypercapnia on tissue oxygen and perfusion response in the normal liver and kidney.

Authors:  Hai-Ling Margaret Cheng
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.